The Canadian government has extended a deal with the vaccine manufacturer Bavarian Nordic for Jynneos (Imvamune in Canada), its monkeypox vaccine. The updated deal adds another $234 million in vaccine doses in the short-term and $180 million in doses doled out in batches through 2032.
According to Fraiser Kansteiner, “Including an earlier $56 million supply contract from June, BN has secured a total supply deal worth up to $470 million in the Great White North. The vaccine specialist says it’ll deliver the majority of Canada’s vaccine order in 2023. Canada can continue to buy additional doses each year after that for the next 10 years.”
To read more, click here.
(Source: Fierce Pharma, September 22nd, 2022)
Tags: HEOR, Vaccines, Healthcare, Therapeutics, Monkeypox
